Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
155 Cards in this Set
- Front
- Back
|
ADRENALINE (INDICATIONS) |
-Anaphylaxis OR severe allergic reaction -Severe life-threatening bronchospasm OR silent chest (patients must only be able to speak in single words AND/OR have haemodynamic compromise AND/OR an ALOC) -Bradycardia with poor perfusion (unresponsive to atropine AND/OR transcutaneous pacing) -Cardiac arrest -Croup (moderate to severe) -Shock unresponsive to adequate fluid resuscitation |
|
|
ADRENALINE (CONTRAINDICATIONS) |
NIL |
|
|
ADRENALINE (PRESENTATION) |
-Ampoule, 1 mg/1 mL (1:1,000) adrenaline (epinephrine) -Ampoule, 1 mg/10 mL (1:10,000) adrenaline (epinephrine) -Prefilled syringe EpiPen® Auto–injector (300 microg) adrenaline (epinephrine) -Prefilled syringe EpiPen® Jr Auto-injector (150 microg) adrenaline (epinephrine) |
|
|
AMIODARONE (INDICATIONS) |
-Cardiac arrest (if refractory to three DCCS) -Sustained conscious VT (haemodynamically stable) |
|
|
AMIODARONE (CONTRAINDICATIONS) |
-For patients who are in cardiac arrest: Tricyclic antidepressant overdose -For patients with sustained conscious VT (haemodynamically stable): Allergy AND/OR Adverse Drug Reaction severe conduction disorders (unless pacemaker or AICD in situ) tricyclic antidepressant overdose current amiodarone therapy concurrent anti-arrhythmic therapy that prolongs the QT interval pregnancy AND/OR lactation |
|
|
AMIODARONE (PRESENTATION) |
-Ampoule, 150 mg/3 mL amiodarone |
|
|
ASPIRIN (INDICATIONS) |
-Suspected ACS -Acute cardiogenic pulmonary oedema |
|
|
ASPIRIN (CONTRAINDICATIONS) |
-Allergy AND/OR Adverse Drug Reaction to aspirin OR any non-steroidal anti-inflammatory drug (NSAID) -Bleeding OR clotting disorders (e.g. haemophilia) -Current GI bleeding OR peptic ulcers -Patients < 18 years |
|
|
ASPIRIN (CONTRAINDICATIONS) |
-Allergy AND/OR Adverse Drug Reaction to aspirin OR any non-steroidal anti-inflammatory drug (NSAID) -Bleeding OR clotting disorders (e.g. haemophilia) -Current GI bleeding OR peptic ulcers -Patients < 18 years |
|
|
ASPIRIN (PRESENTATION) |
Tablet (white), 300 mg aspirin |
|
|
CEFTRIAXONE (INDICATIONS) |
Suspected meningococcal septicaemia (with a non-blanching petechial AND/OR purpuric rash) |
|
|
CEFTRIAXONE (INDICATIONS) |
Suspected meningococcal septicaemia (with a non-blanching petechial AND/OR purpuric rash) |
|
|
CEDTRIAXONE (CONTRAINDICATIONS) |
-Absolute contraindications: Allergy AND/OR Adverse Drug Reaction to cephalosporin antibiotics Known immediate OR severe hypersensitivity to penicillin OR carbapenem based drugs -Relative contraindications (requires consultation with the QAS Clinical Consultation & Advice Line): Patients less than 1 month of age |
|
|
CEFTRIAXONE (INDICATIONS) |
Suspected meningococcal septicaemia (with a non-blanching petechial AND/OR purpuric rash) |
|
|
CEDTRIAXONE (CONTRAINDICATIONS) |
-Absolute contraindications: Allergy AND/OR Adverse Drug Reaction to cephalosporin antibiotics Known immediate OR severe hypersensitivity to penicillin OR carbapenem based drugs -Relative contraindications (requires consultation with the QAS Clinical Consultation & Advice Line): Patients less than 1 month of age |
|
|
CEFTRIAXONE (PRESENTATION) |
Vial (powder), 1 g ceftriaxone |
|
|
FENTANYL (INDICATIONS) |
-Significant pain -Sedation -Autonomic dysreflexia (with systolic BP > 160 mmHg) -Induction for Rapid Sequence Intubation (RSI) NOTE: Morphine is the preferred narcotic agent except under the following circumstances: allergy AND/OR Adverse Drug Reaction to morphine; haemodynamic instability; known/suspected kidney disease; when NAS narcotic administration is the preferred treatment: AND/OR suspected ACS. |
|
|
FENTANYL (INDICATIONS) |
-Significant pain -Sedation -Autonomic dysreflexia (with systolic BP > 160 mmHg) -Induction for Rapid Sequence Intubation (RSI) NOTE: Morphine is the preferred narcotic agent except under the following circumstances: allergy AND/OR Adverse Drug Reaction to morphine; haemodynamic instability; known/suspected kidney disease; when NAS narcotic administration is the preferred treatment: AND/OR suspected ACS. |
|
|
FENTANYL (CONTRAINDICATIONS) |
Allergy AND/OR Adverse Drug Reaction |
|
|
FENTANYL (INDICATIONS) |
-Significant pain -Sedation -Autonomic dysreflexia (with systolic BP > 160 mmHg) -Induction for Rapid Sequence Intubation (RSI) NOTE: Morphine is the preferred narcotic agent except under the following circumstances: allergy AND/OR Adverse Drug Reaction to morphine; haemodynamic instability; known/suspected kidney disease; when NAS narcotic administration is the preferred treatment: AND/OR suspected ACS. |
|
|
FENTANYL (CONTRAINDICATIONS) |
Allergy AND/OR Adverse Drug Reaction |
|
|
FENTANYL (PRESENTATION) |
Ampoule, 100 microg/2 mL fentanyl |
|
|
GLUCAGON (INDICATIONS) |
-Symptomatic hypoglycaemia (with the inability to self-administer oral glucose) -Refractory anaphylaxis with persistent hypotension/shock (unresponsive to 3 x IM adrenaline injections and adequate fluid challenges) |
|
|
GLUCAGON (INDICATIONS) |
-Symptomatic hypoglycaemia (with the inability to self-administer oral glucose) -Refractory anaphylaxis with persistent hypotension/shock (unresponsive to 3 x IM adrenaline injections and adequate fluid challenges) |
|
|
GLUCAGON (CONTRAINDICATIONS) |
Allergy AND/OR Adverse Drug Reaction |
|
|
GLUCAGON (INDICATIONS) |
-Symptomatic hypoglycaemia (with the inability to self-administer oral glucose) -Refractory anaphylaxis with persistent hypotension/shock (unresponsive to 3 x IM adrenaline injections and adequate fluid challenges) |
|
|
GLUCAGON (CONTRAINDICATIONS) |
Allergy AND/OR Adverse Drug Reaction |
|
|
GLUCAGON (PRESENTATION) |
Vials (powder and solvent), 1 mg glucagon (GlucaGen® Hypokit) |
|
|
GLUCOSE GEL (INDICATIONS) |
Symptomatic hypoglycaemia (with the ability to self-administer oral glucose) |
|
|
GLUCOSE GEL (INDICATIONS) |
Symptomatic hypoglycaemia (with the ability to self-administer oral glucose) |
|
|
GLUCOSE GEL (CONTRAINDICATIONS) |
-Unconsciousness -Patients with difficulty swallowing -Patients < 2 years |
|
|
GLUCOSE GEL (INDICATIONS) |
Symptomatic hypoglycaemia (with the ability to self-administer oral glucose) |
|
|
GLUCOSE GEL (CONTRAINDICATIONS) |
-Unconsciousness -Patients with difficulty swallowing -Patients < 2 years |
|
|
GLUCOSE GEL (PRESENTATION) |
Tube, 15 g glucose (Glutose 15™) |
|
|
GLUCOSE 10% (INDICATIONS) |
Symptomatic hypoglycaemia (with the inability to self-administer oral glucose) |
|
|
GLUCOSE GEL (INDICATIONS) |
Symptomatic hypoglycaemia (with the ability to self-administer oral glucose) |
|
|
GLUCOSE GEL (CONTRAINDICATIONS) |
-Unconsciousness -Patients with difficulty swallowing -Patients < 2 years |
|
|
GLUCOSE GEL (PRESENTATION) |
Tube, 15 g glucose (Glutose 15™) |
|
|
GLUCOSE 10% (INDICATIONS) |
Symptomatic hypoglycaemia (with the inability to self-administer oral glucose) |
|
|
GLUCOSE 10% (CONTRAINDICATIONS) |
NIL |
|
|
GLUCOSE GEL (INDICATIONS) |
Symptomatic hypoglycaemia (with the ability to self-administer oral glucose) |
|
|
GLUCOSE GEL (CONTRAINDICATIONS) |
-Unconsciousness -Patients with difficulty swallowing -Patients < 2 years |
|
|
GLUCOSE GEL (PRESENTATION) |
Tube, 15 g glucose (Glutose 15™) |
|
|
GLUCOSE 10% (INDICATIONS) |
Symptomatic hypoglycaemia (with the inability to self-administer oral glucose) |
|
|
GLUCOSE 10% (CONTRAINDICATIONS) |
NIL |
|
|
GLUCOSE 10% (PRESENTATION) |
Viaflex® plastic container, 250 mL glucose monohydrate 10% |
|
|
GLUCOSE GEL (INDICATIONS) |
Symptomatic hypoglycaemia (with the ability to self-administer oral glucose) |
|
|
GLUCOSE GEL (CONTRAINDICATIONS) |
-Unconsciousness -Patients with difficulty swallowing -Patients < 2 years |
|
|
GLUCOSE GEL (PRESENTATION) |
Tube, 15 g glucose (Glutose 15™) |
|
|
GLUCOSE 10% (INDICATIONS) |
Symptomatic hypoglycaemia (with the inability to self-administer oral glucose) |
|
|
GLUCOSE 10% (CONTRAINDICATIONS) |
NIL |
|
|
GLUCOSE 10% (PRESENTATION) |
Viaflex® plastic container, 250 mL glucose monohydrate 10% |
|
|
Glyceryl trinitrate GTN (INDICATIONS) |
-Suspected ACS (with pain) -Acute cardiogenic pulmonary oedema -Autonomic dysreflexia (with a systolic BP ≥ 160 mmHg) -Irukandji syndrome (with a systolic BP ≥ 160 mmHg) |
|
|
Glyceryl trinitrate GTN (CONTRAINDICATIONS) |
-Allergy AND/OR Adverse Drug Reaction -Heart rate < 50 OR > 150 beats per minute -Systolic BP < 100 mmHg -Acute CVA -Head trauma -Phosphodiesterase 5 inhibitor medication administration: Silenafil OR vardenafil in the past 24 hours Tadalafil in the previous 48 hours |
|
|
Glyceryl trinitrate GTN (CONTRAINDICATIONS) |
-Allergy AND/OR Adverse Drug Reaction -Heart rate < 50 OR > 150 beats per minute -Systolic BP < 100 mmHg -Acute CVA -Head trauma -Phosphodiesterase 5 inhibitor medication administration: Silenafil OR vardenafil in the past 24 hours Tadalafil in the previous 48 hours |
|
|
Glyceryl trinitrate GTN (PRESENTATION) |
-Spray (sublingual), 400 microg/dose, 200 doses, nitrolingual pump spray -Ampoule, 50 mg/10 mL glyceryl trinitrate |
|
|
HYDROCORTISONE (INDICATIONS) |
-Asthma (excluding mild) -Acute exacerbation of COPD (with evidence of respiratory distress) -Refractory anaphylaxis with persistent wheeze (and unresponsive to 3 x M adrenaline (epinephrine)) -Suspected, or at risk of, an acute adrenal insufficiency (adrenal crisis) |
|
|
HYDROCORTISONE (INDICATIONS) |
-Asthma (excluding mild) -Acute exacerbation of COPD (with evidence of respiratory distress) -Refractory anaphylaxis with persistent wheeze (and unresponsive to 3 x M adrenaline (epinephrine)) -Suspected, or at risk of, an acute adrenal insufficiency (adrenal crisis) |
|
|
HYDROCORTISONE (CONTRAINDICATIONS) |
Allergy AND/OR Adverse Drug Reaction |
|
|
HYDROCORTISONE (INDICATIONS) |
-Asthma (excluding mild) -Acute exacerbation of COPD (with evidence of respiratory distress) -Refractory anaphylaxis with persistent wheeze (and unresponsive to 3 x M adrenaline (epinephrine)) -Suspected, or at risk of, an acute adrenal insufficiency (adrenal crisis) |
|
|
HYDROCORTISONE (CONTRAINDICATIONS) |
Allergy AND/OR Adverse Drug Reaction |
|
|
HYDROCORTISONE (PRESENTATION) |
Vial (powder), 100 mg hydrocortisone sodium succinate |
|
|
IBUPROFEN (INDICATIONS) |
Moderate pain due to acute inflammation and tissue injury |
|
|
IBUPROFEN (INDICATIONS) |
Moderate pain due to acute inflammation and tissue injury |
|
|
IBUPROFEN (CONTRAINDICATIONS) |
-Allergy AND/OR Adverse Drug Reaction to any NSAID OR aspirin -Concurrent NSAID therapy -Current GI bleeding OR peptic ulcers -Dehydration AND/OR hypovolaemia -Renal impairement -NSAID induced asthma -Heart failure -Pregnancy -Angiotensin converting enzyme (ACE) inhibitor OR Angiotension II receptor blockers (ARBs) -Patients < 13 OR ≥ 65 years -Patients taking anticoagulant medications -Diuretic treatment |
|
|
IBUPROFEN (INDICATIONS) |
Moderate pain due to acute inflammation and tissue injury |
|
|
IBUPROFEN (CONTRAINDICATIONS) |
-Allergy AND/OR Adverse Drug Reaction to any NSAID OR aspirin -Concurrent NSAID therapy -Current GI bleeding OR peptic ulcers -Dehydration AND/OR hypovolaemia -Renal impairement -NSAID induced asthma -Heart failure -Pregnancy -Angiotensin converting enzyme (ACE) inhibitor OR Angiotension II receptor blockers (ARBs) -Patients < 13 OR ≥ 65 years -Patients taking anticoagulant medications -Diuretic treatment |
|
|
IBUPROFEN (PRESENTATION) |
Tablet, 200 mg ibuprofen |
|
|
IBUPROFEN (INDICATIONS) |
Moderate pain due to acute inflammation and tissue injury |
|
|
IBUPROFEN (CONTRAINDICATIONS) |
-Allergy AND/OR Adverse Drug Reaction to any NSAID OR aspirin -Concurrent NSAID therapy -Current GI bleeding OR peptic ulcers -Dehydration AND/OR hypovolaemia -Renal impairement -NSAID induced asthma -Heart failure -Pregnancy -Angiotensin converting enzyme (ACE) inhibitor OR Angiotension II receptor blockers (ARBs) -Patients < 13 OR ≥ 65 years -Patients taking anticoagulant medications -Diuretic treatment |
|
|
IBUPROFEN (PRESENTATION) |
Tablet, 200 mg ibuprofen |
|
|
IPRATROPIUM BROMIDE (INDICATIONS) |
-Moderate bronchospasm (unresponsive to initial QAS salbutamol NEB) -Severe bronchospasm |
|
|
IBUPROFEN (INDICATIONS) |
Moderate pain due to acute inflammation and tissue injury |
|
|
IBUPROFEN (CONTRAINDICATIONS) |
-Allergy AND/OR Adverse Drug Reaction to any NSAID OR aspirin -Concurrent NSAID therapy -Current GI bleeding OR peptic ulcers -Dehydration AND/OR hypovolaemia -Renal impairement -NSAID induced asthma -Heart failure -Pregnancy -Angiotensin converting enzyme (ACE) inhibitor OR Angiotension II receptor blockers (ARBs) -Patients < 13 OR ≥ 65 years -Patients taking anticoagulant medications -Diuretic treatment |
|
|
IBUPROFEN (PRESENTATION) |
Tablet, 200 mg ibuprofen |
|
|
IPRATROPIUM BROMIDE (INDICATIONS) |
-Moderate bronchospasm (unresponsive to initial QAS salbutamol NEB) -Severe bronchospasm |
|
|
IPRATROPIUM BROMIDE (CONTRAINDICATIONS) |
-Allergy AND/OR Adverse Drug Reaction -Patients less than 1 year of age |
|
|
IBUPROFEN (INDICATIONS) |
Moderate pain due to acute inflammation and tissue injury |
|
|
IBUPROFEN (CONTRAINDICATIONS) |
-Allergy AND/OR Adverse Drug Reaction to any NSAID OR aspirin -Concurrent NSAID therapy -Current GI bleeding OR peptic ulcers -Dehydration AND/OR hypovolaemia -Renal impairement -NSAID induced asthma -Heart failure -Pregnancy -Angiotensin converting enzyme (ACE) inhibitor OR Angiotension II receptor blockers (ARBs) -Patients < 13 OR ≥ 65 years -Patients taking anticoagulant medications -Diuretic treatment |
|
|
IBUPROFEN (PRESENTATION) |
Tablet, 200 mg ibuprofen |
|
|
IPRATROPIUM BROMIDE (INDICATIONS) |
-Moderate bronchospasm (unresponsive to initial QAS salbutamol NEB) -Severe bronchospasm |
|
|
IPRATROPIUM BROMIDE (CONTRAINDICATIONS) |
-Allergy AND/OR Adverse Drug Reaction -Patients less than 1 year of age |
|
|
IPRATROPIUM BROMIDE (PRESENTATION) |
Nebule, 250 microg/1 mL ipratropium bromide monohydrate |
|
|
IBUPROFEN (INDICATIONS) |
Moderate pain due to acute inflammation and tissue injury |
|
|
IBUPROFEN (CONTRAINDICATIONS) |
-Allergy AND/OR Adverse Drug Reaction to any NSAID OR aspirin -Concurrent NSAID therapy -Current GI bleeding OR peptic ulcers -Dehydration AND/OR hypovolaemia -Renal impairement -NSAID induced asthma -Heart failure -Pregnancy -Angiotensin converting enzyme (ACE) inhibitor OR Angiotension II receptor blockers (ARBs) -Patients < 13 OR ≥ 65 years -Patients taking anticoagulant medications -Diuretic treatment |
|
|
IBUPROFEN (PRESENTATION) |
Tablet, 200 mg ibuprofen |
|
|
IPRATROPIUM BROMIDE (INDICATIONS) |
-Moderate bronchospasm (unresponsive to initial QAS salbutamol NEB) -Severe bronchospasm |
|
|
IPRATROPIUM BROMIDE (CONTRAINDICATIONS) |
-Allergy AND/OR Adverse Drug Reaction -Patients less than 1 year of age |
|
|
IPRATROPIUM BROMIDE (PRESENTATION) |
Nebule, 250 microg/1 mL ipratropium bromide monohydrate |
|
|
METHOXYFLURANE (INDICATIONS) |
PAIN |
|
|
METHOXYFLURANE (CONTRAINDICATIONS) |
-Allergy AND/OR Adverse Drug Reaction -Patients < 1 year -History of significant liver or renal disease -History of malignant hyperthermia |
|
|
METHOXYFLURANE (PRESENTATION) |
Bottle, 3 mL methoxyflurane |
|
|
MIDAZOLAM (INDICATIONS) |
-Generalised seizures/focal seizures (GSC ≤ 12) -Sedation: for maintenance of an established SAD/ETT for procedures (e.g. TCP or cardioversion) CPR induced consciousness to facilitate safe assessment and treatment of the agitated head injured patient as an adjunct to opiate analgesia (fracture splinting/extrication/burns) for ketamine emergence -Acute behavioural disturbance (with a SAT score ≥ 2) unresponsive to droperidol (max dose) administration |
|
|
MIDAZOLAM (INDICATIONS) |
-Generalised seizures/focal seizures (GSC ≤ 12) -Sedation: for maintenance of an established SAD/ETT for procedures (e.g. TCP or cardioversion) CPR induced consciousness to facilitate safe assessment and treatment of the agitated head injured patient as an adjunct to opiate analgesia (fracture splinting/extrication/burns) for ketamine emergence -Acute behavioural disturbance (with a SAT score ≥ 2) unresponsive to droperidol (max dose) administration |
|
|
MIDAZOLAM (CONTRAINDICATIONS) |
Allergy AND/OR Adverse Drug Reaction |
|
|
MIDAZOLAM (INDICATIONS) |
-Generalised seizures/focal seizures (GSC ≤ 12) -Sedation: for maintenance of an established SAD/ETT for procedures (e.g. TCP or cardioversion) CPR induced consciousness to facilitate safe assessment and treatment of the agitated head injured patient as an adjunct to opiate analgesia (fracture splinting/extrication/burns) for ketamine emergence -Acute behavioural disturbance (with a SAT score ≥ 2) unresponsive to droperidol (max dose) administration |
|
|
MIDAZOLAM (CONTRAINDICATIONS) |
Allergy AND/OR Adverse Drug Reaction |
|
|
MIDAZOLAM (PRESENTATION) |
Ampoule, 5 mg/1 mL midazolam |
|
|
MORPHINE (INDICATIONS) |
-Significant pain -Sedation -Autonomic dysreflexia (with a systolic BP > 160 mmHg) NOTE: Morphine is the preferred narcotic agent except under the following circumstances: allergy AND/OR Adverse Drug Reaction; haemodynamic instability; known/suspected kidney disease; when NAS narcotic administration is the preferred treatment; AND/OR suspected ACS. |
|
|
MORPHINE (INDICATIONS) |
-Significant pain -Sedation -Autonomic dysreflexia (with a systolic BP > 160 mmHg) NOTE: Morphine is the preferred narcotic agent except under the following circumstances: allergy AND/OR Adverse Drug Reaction; haemodynamic instability; known/suspected kidney disease; when NAS narcotic administration is the preferred treatment; AND/OR suspected ACS. |
|
|
MORPHINE (CONTRAINDICATIONS) |
-Allergy and/or Adverse Drug Reaction -Kidney disease (renal failure) |
|
|
MORPHINE (INDICATIONS) |
-Significant pain -Sedation -Autonomic dysreflexia (with a systolic BP > 160 mmHg) NOTE: Morphine is the preferred narcotic agent except under the following circumstances: allergy AND/OR Adverse Drug Reaction; haemodynamic instability; known/suspected kidney disease; when NAS narcotic administration is the preferred treatment; AND/OR suspected ACS. |
|
|
MORPHINE (CONTRAINDICATIONS) |
-Allergy and/or Adverse Drug Reaction -Kidney disease (renal failure) |
|
|
MORPHINE (PRESENTATION) |
Ampoule, 10 mg/1 mL morphine sulphate pentahydrate |
|
|
ONDANSETRON (INDICATIONS) |
Significant nausea AND/OR vomiting |
|
|
ONDANSETRON (INDICATIONS) |
Significant nausea AND/OR vomiting |
|
|
ONDANSETRON (CONTRAINDICATIONS) |
-Abolute contraindications: Allergy AND/OR Adverse Drug Reaction Congenital long QT syndrome Current apomorphine therapy (used in severe Parkinson's disease) Patients < 2 years of age -Relative contraindications: First trimester pregnancy (may only be administered for extreme and uncontrolled hyperemesis) |
|
|
ONDANSETRON (INDICATIONS) |
Significant nausea AND/OR vomiting |
|
|
ONDANSETRON (CONTRAINDICATIONS) |
-Abolute contraindications: Allergy AND/OR Adverse Drug Reaction Congenital long QT syndrome Current apomorphine therapy (used in severe Parkinson's disease) Patients < 2 years of age -Relative contraindications: First trimester pregnancy (may only be administered for extreme and uncontrolled hyperemesis) |
|
|
ONDANSETRON (PRESENTATION) |
-Ampoule, 4 mg/2 mL ondansetron -Orally Disintegrating Tablet (ODT), 4 mg ondansetron |
|
|
OXYTOCIN (INDICATIONS) |
-Active management of the third stage of labour (following confirmed delivery of all foetuses) AND the prevention of primary post-partum haemorrhage -Management of uncontrolled primary or secondary postpartum haemorrhage |
|
|
OXYTOCIN (INDICATIONS) |
-Active management of the third stage of labour (following confirmed delivery of all foetuses) AND the prevention of primary post-partum haemorrhage -Management of uncontrolled primary or secondary postpartum haemorrhage |
|
|
OXYTOCIN (CONTRAINDICATIONS) |
-Allergy AND/OR Adverse Drug Reaction -Undelivered foetuses |
|
|
OXYTOCIN (INDICATIONS) |
-Active management of the third stage of labour (following confirmed delivery of all foetuses) AND the prevention of primary post-partum haemorrhage -Management of uncontrolled primary or secondary postpartum haemorrhage |
|
|
OXYTOCIN (CONTRAINDICATIONS) |
-Allergy AND/OR Adverse Drug Reaction -Undelivered foetuses |
|
|
OXYTOCIN (PRESENTATION) |
Ampoule, 10 International units (IU) /1 mL |
|
|
OXYTOCIN (INDICATIONS) |
-Active management of the third stage of labour (following confirmed delivery of all foetuses) AND the prevention of primary post-partum haemorrhage -Management of uncontrolled primary or secondary postpartum haemorrhage |
|
|
OXYTOCIN (CONTRAINDICATIONS) |
-Allergy AND/OR Adverse Drug Reaction -Undelivered foetuses |
|
|
OXYTOCIN (PRESENTATION) |
Ampoule, 10 International units (IU) /1 mL |
|
|
PARACETAMOL (INDICATIONS) |
-Mild to moderate pain -Fever (causing distress) |
|
|
OXYTOCIN (INDICATIONS) |
-Active management of the third stage of labour (following confirmed delivery of all foetuses) AND the prevention of primary post-partum haemorrhage -Management of uncontrolled primary or secondary postpartum haemorrhage |
|
|
OXYTOCIN (CONTRAINDICATIONS) |
-Allergy AND/OR Adverse Drug Reaction -Undelivered foetuses |
|
|
OXYTOCIN (PRESENTATION) |
Ampoule, 10 International units (IU) /1 mL |
|
|
PARACETAMOL (INDICATIONS) |
-Mild to moderate pain -Fever (causing distress) |
|
|
PARACETAMOL (CONTRAINDICATIONS) |
-Allergy AND/OR Adverse Drug Reaction -Patients < 1 month old |
|
|
OXYTOCIN (INDICATIONS) |
-Active management of the third stage of labour (following confirmed delivery of all foetuses) AND the prevention of primary post-partum haemorrhage -Management of uncontrolled primary or secondary postpartum haemorrhage |
|
|
OXYTOCIN (CONTRAINDICATIONS) |
-Allergy AND/OR Adverse Drug Reaction -Undelivered foetuses |
|
|
OXYTOCIN (PRESENTATION) |
Ampoule, 10 International units (IU) /1 mL |
|
|
PARACETAMOL (INDICATIONS) |
-Mild to moderate pain -Fever (causing distress) |
|
|
PARACETAMOL (CONTRAINDICATIONS) |
-Allergy AND/OR Adverse Drug Reaction -Patients < 1 month old |
|
|
PARACETAMOL (PRESENTATION) |
-Tablet, 500 mg paracetamol -Elixir, 120 mg/5 mL paracetamol |
|
|
OXYTOCIN (INDICATIONS) |
-Active management of the third stage of labour (following confirmed delivery of all foetuses) AND the prevention of primary post-partum haemorrhage -Management of uncontrolled primary or secondary postpartum haemorrhage |
|
|
OXYTOCIN (CONTRAINDICATIONS) |
-Allergy AND/OR Adverse Drug Reaction -Undelivered foetuses |
|
|
OXYTOCIN (PRESENTATION) |
Ampoule, 10 International units (IU) /1 mL |
|
|
PARACETAMOL (INDICATIONS) |
-Mild to moderate pain -Fever (causing distress) |
|
|
PARACETAMOL (CONTRAINDICATIONS) |
-Allergy AND/OR Adverse Drug Reaction -Patients < 1 month old |
|
|
PARACETAMOL (PRESENTATION) |
-Tablet, 500 mg paracetamol -Elixir, 120 mg/5 mL paracetamol |
|
|
SALBUTAMOL (INDICATIONS) |
-Bronchospasm -Suspected hyperkalaemia (with QRS widening AND/OR AV dissociation) |
|
|
OXYTOCIN (INDICATIONS) |
-Active management of the third stage of labour (following confirmed delivery of all foetuses) AND the prevention of primary post-partum haemorrhage -Management of uncontrolled primary or secondary postpartum haemorrhage |
|
|
OXYTOCIN (CONTRAINDICATIONS) |
-Allergy AND/OR Adverse Drug Reaction -Undelivered foetuses |
|
|
OXYTOCIN (PRESENTATION) |
Ampoule, 10 International units (IU) /1 mL |
|
|
PARACETAMOL (INDICATIONS) |
-Mild to moderate pain -Fever (causing distress) |
|
|
PARACETAMOL (CONTRAINDICATIONS) |
-Allergy AND/OR Adverse Drug Reaction -Patients < 1 month old |
|
|
PARACETAMOL (PRESENTATION) |
-Tablet, 500 mg paracetamol -Elixir, 120 mg/5 mL paracetamol |
|
|
SALBUTAMOL (INDICATIONS) |
-Bronchospasm -Suspected hyperkalaemia (with QRS widening AND/OR AV dissociation) |
|
|
SALBUTAMOL (CONTRAINDICATIONS) |
-Allergy AND/OR Adverse Drug Reaction -Patients less than 1 year of age |
|
|
OXYTOCIN (INDICATIONS) |
-Active management of the third stage of labour (following confirmed delivery of all foetuses) AND the prevention of primary post-partum haemorrhage -Management of uncontrolled primary or secondary postpartum haemorrhage |
|
|
OXYTOCIN (CONTRAINDICATIONS) |
-Allergy AND/OR Adverse Drug Reaction -Undelivered foetuses |
|
|
OXYTOCIN (PRESENTATION) |
Ampoule, 10 International units (IU) /1 mL |
|
|
PARACETAMOL (INDICATIONS) |
-Mild to moderate pain -Fever (causing distress) |
|
|
PARACETAMOL (CONTRAINDICATIONS) |
-Allergy AND/OR Adverse Drug Reaction -Patients < 1 month old |
|
|
PARACETAMOL (PRESENTATION) |
-Tablet, 500 mg paracetamol -Elixir, 120 mg/5 mL paracetamol |
|
|
SALBUTAMOL (INDICATIONS) |
-Bronchospasm -Suspected hyperkalaemia (with QRS widening AND/OR AV dissociation) |
|
|
SALBUTAMOL (CONTRAINDICATIONS) |
-Allergy AND/OR Adverse Drug Reaction -Patients less than 1 year of age |
|
|
SALBUTAMOL (PRESENTATION) |
-Metered Dose Inhaler, 100 microg/puff salbutamol -Nebule, 2.5 mg/2.5 mL salbutamol -Nebule, 5 mg/2.5 mL salbutamol -Ampoule, 500 mcg/1 mL salbutamol |
